Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2007 4
2008 1
2009 5
2010 12
2011 9
2012 11
2013 5
2014 6
2015 7
2016 6
2017 3
2018 3
2019 9
2020 9
2021 14
2022 9
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy.
Russo S, Feola S, Feodoroff M, Chiaro J, Antignani G, Fusciello M, D'Alessio F, Hamdan F, Pellinen T, Mölsä R, Tripodi L, Pastore L, Grönholm M, Cerullo V. Russo S, et al. Among authors: cerullo v. Mol Ther Oncol. 2024 Jan 26;32(1):200766. doi: 10.1016/j.omton.2024.200766. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596301 Free PMC article.
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.
Feola S, Hamdan F, Russo S, Chiaro J, Fusciello M, Feodoroff M, Antignani G, D'Alessio F, Mölsä R, Stigzelius V, Bottega P, Pesonen S, Leusen J, Grönholm M, Cerullo V. Feola S, et al. Among authors: cerullo v. J Immunother Cancer. 2024 Mar 8;12(3):e008342. doi: 10.1136/jitc-2023-008342. J Immunother Cancer. 2024. PMID: 38458776 Free PMC article.
PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.
Feola S, Chiaro J, Fusciello M, Russo S, Kleino I, Ylösmäki L, Kekäläinen E, Hästbacka J, Pekkarinen PT, Ylösmäki E, Capone S, Folgori A, Raggioli A, Boni C, Tiezzi C, Vecchi A, Gelzo M, Kared H, Nardin A, Fehlings M, Barban V, Ahokas P, Viitala T, Castaldo G, Pastore L, Porter P, Pesonen S, Cerullo V. Feola S, et al. Among authors: cerullo v. Int J Biol Macromol. 2024 Mar;262(Pt 1):129926. doi: 10.1016/j.ijbiomac.2024.129926. Epub 2024 Feb 6. Int J Biol Macromol. 2024. PMID: 38331062
Exploring the DNA2-PNA heterotriplex formation in targeting the Bcl-2 gene promoter: A structural insight by physico-chemical and microsecond-scale MD investigation.
Falanga AP, Lupia A, Tripodi L, Morgillo CM, Moraca F, Roviello GN, Catalanotti B, Amato J, Pastore L, Cerullo V, D'Errico S, Piccialli G, Oliviero G, Borbone N. Falanga AP, et al. Among authors: cerullo v. Heliyon. 2024 Jan 22;10(3):e24599. doi: 10.1016/j.heliyon.2024.e24599. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38317891 Free PMC article.
Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model.
Garofalo M, Wieczorek M, Anders I, Staniszewska M, Lazniewski M, Prygiel M, Zasada AA, Szczepińska T, Plewczynski D, Salmaso S, Caliceti P, Cerullo V, Alemany R, Rinner B, Pancer K, Kuryk L. Garofalo M, et al. Among authors: cerullo v. Front Oncol. 2023 Nov 20;13:1259314. doi: 10.3389/fonc.2023.1259314. eCollection 2023. Front Oncol. 2023. PMID: 38053658 Free PMC article.
Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.
Manfredi F, Stasi L, Buonanno S, Marzuttini F, Noviello M, Mastaglio S, Abbati D, Potenza A, Balestrieri C, Cianciotti BC, Tassi E, Feola S, Toffalori C, Punta M, Magnani Z, Camisa B, Tiziano E, Lupo-Stanghellini MT, Branca RM, Lehtiö J, Sikanen TM, Haapala MJ, Cerullo V, Casucci M, Vago L, Ciceri F, Bonini C, Ruggiero E. Manfredi F, et al. Among authors: cerullo v. Sci Adv. 2023 Dec;9(48):eadg8014. doi: 10.1126/sciadv.adg8014. Epub 2023 Dec 1. Sci Adv. 2023. PMID: 38039364 Free PMC article.
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.
Chiaro J, Antignani G, Feola S, Feodoroff M, Martins B, Cojoc H, Russo S, Fusciello M, Hamdan F, Ferrari V, Ciampi D, Ilonen I, Räsänen J, Mäyränpää M, Partanen J, Koskela S, Honkanen J, Halonen J, Kuryk L, Rescigno M, Grönholm M, Branca RM, Lehtiö J, Cerullo V. Chiaro J, et al. Among authors: cerullo v. Nat Commun. 2023 Nov 3;14(1):7056. doi: 10.1038/s41467-023-42668-7. Nat Commun. 2023. PMID: 37923723 Free PMC article.
Translational Aspects of Epithelioid Sarcoma: Current Consensus.
Grünewald TGP, Postel-Vinay S, Nakayama RT, Berlow NE, Bolzicco A, Cerullo V, Dermawan JK, Frezza AM, Italiano A, Jin JX, Le Loarer F, Martin-Broto J, Pecora A, Perez-Martinez A, Tam YB, Tirode F, Trama A, Pasquali S, Vescia M, Wortmann L, Wortmann M, Yoshida A, Webb K, Huang PH, Keller C, Antonescu CR. Grünewald TGP, et al. Among authors: cerullo v. Clin Cancer Res. 2024 Mar 15;30(6):1079-1092. doi: 10.1158/1078-0432.CCR-23-2174. Clin Cancer Res. 2024. PMID: 37916971 Review.
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.
Tripodi L, Feola S, Granata I, Whalley T, Passariello M, Capasso C, Coluccino L, Vitale M, Scalia G, Gentile L, De Lorenzo C, Guarracino MR, Castaldo G, D'Argenio V, Szomolay B, Cerullo V, Pastore L. Tripodi L, et al. Among authors: cerullo v. iScience. 2023 Aug 19;26(10):107668. doi: 10.1016/j.isci.2023.107668. eCollection 2023 Oct 20. iScience. 2023. PMID: 37720092 Free PMC article.
Personalizing Oncolytic Virotherapy.
Hamdan F, Fusciello M, Cerullo V. Hamdan F, et al. Among authors: cerullo v. Hum Gene Ther. 2023 Sep;34(17-18):870-877. doi: 10.1089/hum.2023.122. Hum Gene Ther. 2023. PMID: 37698876 Review.
117 results